Amylyx Pharmaceuticals (AMLX) Receivables (2022 - 2025)
Historic Receivables for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to $232000.0.
- Amylyx Pharmaceuticals' Receivables fell 8732.93% to $232000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $232000.0, marking a year-over-year decrease of 8732.93%. This contributed to the annual value of $547000.0 for FY2024, which is 9865.1% down from last year.
- Amylyx Pharmaceuticals' Receivables amounted to $232000.0 in Q3 2025, which was down 8732.93% from $203000.0 recorded in Q2 2025.
- Over the past 5 years, Amylyx Pharmaceuticals' Receivables peaked at $40.6 million during Q4 2023, and registered a low of $137000.0 during Q3 2022.
- Its 4-year average for Receivables is $12.8 million, with a median of $4.2 million in 2024.
- In the last 5 years, Amylyx Pharmaceuticals' Receivables skyrocketed by 2139854.01% in 2023 and then tumbled by 9865.1% in 2024.
- Quarter analysis of 4 years shows Amylyx Pharmaceuticals' Receivables stood at $15.8 million in 2022, then skyrocketed by 156.55% to $40.6 million in 2023, then crashed by 98.65% to $547000.0 in 2024, then tumbled by 57.59% to $232000.0 in 2025.
- Its Receivables stands at $232000.0 for Q3 2025, versus $203000.0 for Q2 2025 and $400000.0 for Q1 2025.